[{"id":"00c35bc1-188e-4099-b934-09f9bbb72f40","acronym":"","url":"https://clinicaltrials.gov/study/NCT01391143","created_at":"2021-01-18T05:42:37.598Z","updated_at":"2024-07-02T16:36:17.398Z","phase":"Phase 1","brief_title":"Safety Study of MGA271 in Refractory Cancer","source_id_and_acronym":"NCT01391143","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" CD276 overexpression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Completed","enrollment":" Enrollment 179","initiation":"Initiation: 07/01/2011","start_date":" 07/01/2011","primary_txt":" Primary completion: 04/18/2019","primary_completion_date":" 04/18/2019","study_txt":" Completion: 04/18/2019","study_completion_date":" 04/18/2019","last_update_posted":"2022-02-08"}]